<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31714900</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><Volume>130</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>02</Day></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS.</ArticleTitle><Pagination><StartPage>1139</StartPage><EndPage>1155</EndPage><MedlinePgn>1139-1155</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI130988</ELocationID><ELocationID EIdType="pii" ValidYN="Y">130988</ELocationID><Abstract><AbstractText>Cortical hyperexcitability and mislocalization of the RNA-binding protein TDP43 are highly conserved features in amyotrophic lateral sclerosis (ALS). Nevertheless, the relationship between these phenomena remains poorly defined. Here, we showed that hyperexcitability recapitulates TDP43 pathology by upregulating shortened TDP43 (sTDP43) splice isoforms. These truncated isoforms accumulated in the cytoplasm and formed insoluble inclusions that sequestered full-length TDP43 via preserved N-terminal interactions. Consistent with these findings, sTDP43 overexpression was toxic to mammalian neurons, suggesting neurodegeneration arising from complementary gain- and loss-of-function mechanisms. In humans and mice, sTDP43 transcripts were enriched in vulnerable motor neurons, and we observed a striking accumulation of sTDP43 within neurons and glia of ALS patients. Collectively, these studies uncover a pathogenic role for alternative TDP43 isoforms in ALS, and implicate sTDP43 as a key contributor to the susceptibility of motor neurons in this disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weskamp</LastName><ForeName>Kaitlin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tank</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miguez</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McBride</LastName><ForeName>Jonathon P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cellular and Molecular Biology Program, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez</LastName><ForeName>Nicol&#xe1;s B</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cellular and Molecular Biology Program, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ziqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Carmen Moreno</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Centre for Craniofacial and Regenerative Biology, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serio</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Craniofacial and Regenerative Biology, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sreedharan</LastName><ForeName>Jemeen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barmada</LastName><ForeName>Sami J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cellular and Molecular Biology Program, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG053760</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097542</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/K010611/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>T32 GM007863</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25 GM086262</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>SREEDHARAN/JAN13/943-795</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SREEDHARAN/APR16/849-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Cell Biology</Keyword><Keyword MajorTopicYN="N">Molecular pathology</Keyword><Keyword MajorTopicYN="N">Neuroscience</Keyword><Keyword MajorTopicYN="N">Protein misfolding</Keyword></KeywordList><CoiStatement><b>Conflict of interest:</b> The authors have declared that no conflict of interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31714900</ArticleId><ArticleId IdType="pmc">PMC7269575</ArticleId><ArticleId IdType="doi">10.1172/JCI130988</ArticleId><ArticleId IdType="pii">130988</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004;27:723&#x2013;749. doi: 10.1146/annurev.neuro.27.070203.144244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.27.070203.144244</ArticleId><ArticleId IdType="pubmed">15217349</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M. Molecular neuropathology of TDP-43 proteinopathies. Int J Mol Sci. 2009;10(1):232&#x2013;246. doi: 10.3390/ijms10010232.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms10010232</ArticleId><ArticleId IdType="pmc">PMC2662455</ArticleId><ArticleId IdType="pubmed">19333444</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, et al. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol. 2011;122(6):673&#x2013;690. doi: 10.1007/s00401-011-0907-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0907-y</ArticleId><ArticleId IdType="pmc">PMC3277860</ArticleId><ArticleId IdType="pubmed">22083254</ArticleId></ArticleIdList></Reference><Reference><Citation>Seilhean D, et al. Accumulation of TDP-43 and alpha-actin in an amyotrophic lateral sclerosis patient with the K17I ANG mutation. Acta Neuropathol. 2009;118(4):561&#x2013;573. doi: 10.1007/s00401-009-0545-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0545-9</ArticleId><ArticleId IdType="pubmed">19449021</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S, et al. Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. Brain. 2016;139(Pt 2):452&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4805085</ArticleId><ArticleId IdType="pubmed">26674655</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN, et al. Novel mutations support a role for Profilin 1 in the pathogenesis of ALS. Neurobiol Aging. 2015;36(3):1602.e17&#x2013;1602.e27. doi: 10.1016/j.neurobiolaging.2014.10.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.10.032</ArticleId><ArticleId IdType="pmc">PMC4357530</ArticleId><ArticleId IdType="pubmed">25499087</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HX, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477(7363):211&#x2013;215. doi: 10.1038/nature10353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10353</ArticleId><ArticleId IdType="pmc">PMC3169705</ArticleId><ArticleId IdType="pubmed">21857683</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68(5):857&#x2013;864. doi: 10.1016/j.neuron.2010.11.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.036</ArticleId><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495(7442):467&#x2013;473. doi: 10.1038/nature11922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11922</ArticleId><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer BC, et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 2010;119(4):409&#x2013;419. doi: 10.1007/s00401-010-0659-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0659-0</ArticleId><ArticleId IdType="pmc">PMC2880609</ArticleId><ArticleId IdType="pubmed">20198480</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu LS, Cheng WC, Shen CK. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. J Biol Chem. 2012;287(33):27335&#x2013;27344. doi: 10.1074/jbc.M112.359000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.359000</ArticleId><ArticleId IdType="pmc">PMC3431639</ArticleId><ArticleId IdType="pubmed">22718760</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y, et al. Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain. 2013;136(Pt 5):1371&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pubmed">23449777</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton CF, et al. TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem. 2010;285(9):6826&#x2013;6834. doi: 10.1074/jbc.M109.061846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.061846</ArticleId><ArticleId IdType="pmc">PMC2825476</ArticleId><ArticleId IdType="pubmed">20040602</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci. 2010;30(2):639&#x2013;649. doi: 10.1523/JNEUROSCI.4988-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4988-09.2010</ArticleId><ArticleId IdType="pmc">PMC2821110</ArticleId><ArticleId IdType="pubmed">20071528</ArticleId></ArticleIdList></Reference><Reference><Citation>Archbold HC, et al. TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. Sci Rep. 2018;8(1):4606. doi: 10.1038/s41598-018-22858-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-22858-w</ArticleId><ArticleId IdType="pmc">PMC5854632</ArticleId><ArticleId IdType="pubmed">29545601</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, et al. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain. 2011;134(Pt 9):2610&#x2013;2626.</Citation><ArticleIdList><ArticleId IdType="pubmed">21752789</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA. 2010;107(8):3858&#x2013;3863. doi: 10.1073/pnas.0912417107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0912417107</ArticleId><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayton RD, et al. Selective forelimb impairment in rats expressing a pathological TDP-43 25&#x2009;kDa C-terminal fragment to mimic amyotrophic lateral sclerosis. Mol Ther. 2013;21(7):1324&#x2013;1334. doi: 10.1038/mt.2013.88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.88</ArticleId><ArticleId IdType="pmc">PMC3702099</ArticleId><ArticleId IdType="pubmed">23689600</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatom JB, et al. Mimicking aspects of frontotemporal lobar degeneration and Lou Gehrig&#x2019;s disease in rats via TDP-43 overexpression. Mol Ther. 2009;17(4):607&#x2013;613. doi: 10.1038/mt.2009.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2009.3</ArticleId><ArticleId IdType="pmc">PMC2835101</ArticleId><ArticleId IdType="pubmed">19223871</ArticleId></ArticleIdList></Reference><Reference><Citation>Voigt A, et al. TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PLoS One. 2010;5(8):e12247. doi: 10.1371/journal.pone.0012247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0012247</ArticleId><ArticleId IdType="pmc">PMC2923622</ArticleId><ArticleId IdType="pubmed">20806063</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. A Drosophila model for TDP-43 proteinopathy. Proc Natl Acad Sci USA. 2010;107(7):3169&#x2013;3174. doi: 10.1073/pnas.0913602107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0913602107</ArticleId><ArticleId IdType="pmc">PMC2840283</ArticleId><ArticleId IdType="pubmed">20133767</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet. 2010;19(4):671&#x2013;683. doi: 10.1093/hmg/ddp534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp534</ArticleId><ArticleId IdType="pubmed">19959528</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid B, et al. Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth. Proc Natl Acad Sci USA. 2013;110(13):4986&#x2013;4991. doi: 10.1073/pnas.1218311110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1218311110</ArticleId><ArticleId IdType="pmc">PMC3612625</ArticleId><ArticleId IdType="pubmed">23457265</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida A, et al. Non-human primate model of amyotrophic lateral sclerosis with cytoplasmic mislocalization of TDP-43. Brain. 2012;135(Pt 3):833&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286326</ArticleId><ArticleId IdType="pubmed">22252998</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson KL, et al. Initial gene vector dosing for studying symptomatology of amyotrophic lateral sclerosis in non-human primates. J Med Primatol. 2015;44(2):66&#x2013;75. doi: 10.1111/jmp.12162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jmp.12162</ArticleId><ArticleId IdType="pmc">PMC4385002</ArticleId><ArticleId IdType="pubmed">25639184</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain. 2008;131(Pt 6):1540&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">18469020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai K, et al. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(7):734&#x2013;738. doi: 10.1136/jnnp-2011-301782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-301782</ArticleId><ArticleId IdType="pubmed">22566594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai K, et al. Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain. 2006;129(Pt 4):953&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pubmed">16467388</ArticleId></ArticleIdList></Reference><Reference><Citation>Enterzari-Taher M, Eisen A, Stewart H, Nakajima M. Abnormalities of cortical inhibitory neurons in amyotrophic lateral sclerosis. Muscle Nerve. 1997;20(1):65&#x2013;71. doi: 10.1002/(SICI)1097-4598(199701)20:1&lt;65::AID-MUS9&gt;3.0.CO;2-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4598(199701)20:1&lt;65::AID-MUS9&gt;3.0.CO;2-F</ArticleId><ArticleId IdType="pubmed">8995585</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanette G, Tamburin S, Manganotti P, Refatti N, Forgione A, Rizzuto N. Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis. Clin Neurophysiol. 2002;113(11):1688&#x2013;1697. doi: 10.1016/S1388-2457(02)00288-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1388-2457(02)00288-2</ArticleId><ArticleId IdType="pubmed">12417221</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, et al. Cortical function in asymptomatic carriers and patients with C9orf72 amyotrophic lateral sclerosis. JAMA Neurol. 2015;72(11):1268&#x2013;1274. doi: 10.1001/jamaneurol.2015.1872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.1872</ArticleId><ArticleId IdType="pmc">PMC4707047</ArticleId><ArticleId IdType="pubmed">26348842</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Cheah BC, Kiernan MC. Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis. Exp Neurol. 2009;220(1):177&#x2013;182. doi: 10.1016/j.expneurol.2009.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2009.08.017</ArticleId><ArticleId IdType="pubmed">19716820</ArticleId></ArticleIdList></Reference><Reference><Citation>Karandreas N, Papadopoulou M, Kokotis P, Papapostolou A, Tsivgoulis G, Zambelis T. Impaired interhemispheric inhibition in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007;8(2):112&#x2013;118. doi: 10.1080/17482960601030113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960601030113</ArticleId><ArticleId IdType="pubmed">17453640</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura N, et al. Increased nodal persistent Na+ currents in human neuropathy and motor neuron disease estimated by latent addition. Clin Neurophysiol. 2006;117(11):2451&#x2013;2458. doi: 10.1016/j.clinph.2006.07.309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2006.07.309</ArticleId><ArticleId IdType="pubmed">16996798</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya K, et al. Markedly reduced axonal potassium channel expression in human sporadic amyotrophic lateral sclerosis: an immunohistochemical study. Exp Neurol. 2011;232(2):149&#x2013;153. doi: 10.1016/j.expneurol.2011.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2011.08.015</ArticleId><ArticleId IdType="pubmed">21906595</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, et al. Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(7-8):580&#x2013;588. doi: 10.1080/21678421.2016.1188961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1188961</ArticleId><ArticleId IdType="pubmed">27249331</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo JJ, et al. Hyperexcitability of cultured spinal motoneurons from presymptomatic ALS mice. J Neurophysiol. 2004;91(1):571&#x2013;575. doi: 10.1152/jn.00665.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00665.2003</ArticleId><ArticleId IdType="pubmed">14523070</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieri M, et al. Altered excitability of motor neurons in a transgenic mouse model of familial amyotrophic lateral sclerosis. Neurosci Lett. 2003;351(3):153&#x2013;156. doi: 10.1016/j.neulet.2003.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2003.07.010</ArticleId><ArticleId IdType="pubmed">14623129</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zundert B, et al. Neonatal neuronal circuitry shows hyperexcitable disturbance in a mouse model of the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. J Neurosci. 2008;28(43):10864&#x2013;10874. doi: 10.1523/JNEUROSCI.1340-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1340-08.2008</ArticleId><ArticleId IdType="pmc">PMC3844745</ArticleId><ArticleId IdType="pubmed">18945894</ArticleId></ArticleIdList></Reference><Reference><Citation>Saba L, et al. Altered functionality, morphology, and vesicular glutamate transporter expression of cortical motor neurons from a presymptomatic mouse model of amyotrophic lateral sclerosis. Cereb Cortex. 2016;26(4):1512&#x2013;1528. doi: 10.1093/cercor/bhu317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhu317</ArticleId><ArticleId IdType="pubmed">25596588</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieri M, Carunchio I, Curcio L, Mercuri NB, Zona C. Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis. Exp Neurol. 2009;215(2):368&#x2013;379. doi: 10.1016/j.expneurol.2008.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.11.002</ArticleId><ArticleId IdType="pubmed">19071115</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger BJ, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7(1):1&#x2013;11. doi: 10.1016/j.celrep.2014.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.03.019</ArticleId><ArticleId IdType="pmc">PMC4023477</ArticleId><ArticleId IdType="pubmed">24703839</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin AC, et al. Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nat Commun. 2015;6:5999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338554</ArticleId><ArticleId IdType="pubmed">25580746</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9orf72 repeat expansion. Sci Transl Med. 2013;5(208):208ra149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron. 2013;78(5):785&#x2013;798. doi: 10.1016/j.neuron.2013.05.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.05.029</ArticleId><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam RS, T&#xf6;pfer FM, Wood PG, Busskamp V, Bamberg E. Functional maturation of human stem cell-derived neurons in long-term cultures. PLoS One. 2017;12(1):e0169506. doi: 10.1371/journal.pone.0169506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0169506</ArticleId><ArticleId IdType="pmc">PMC5215418</ArticleId><ArticleId IdType="pubmed">28052116</ArticleId></ArticleIdList></Reference><Reference><Citation>Busskamp V, et al. Rapid neurogenesis through transcriptional activation in human stem cells. Mol Syst Biol. 2014;10:760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299601</ArticleId><ArticleId IdType="pubmed">25403753</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, et al. Fibroblast growth factor 2 regulates activity and gene expression of human post-mitotic excitatory neurons. J Neurochem. 2018;145(3):188&#x2013;203. doi: 10.1111/jnc.14255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14255</ArticleId><ArticleId IdType="pmc">PMC5924590</ArticleId><ArticleId IdType="pubmed">29168882</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang IF, Wu LS, Chang HY, Shen CK. TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J Neurochem. 2008;105(3):797&#x2013;806. doi: 10.1111/j.1471-4159.2007.05190.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.05190.x</ArticleId><ArticleId IdType="pubmed">18088371</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwenk BM, et al. TDP-43 loss of function inhibits endosomal trafficking and alters trophic signaling in neurons. EMBO J. 2016;35(21):2350&#x2013;2370. doi: 10.15252/embj.201694221.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201694221</ArticleId><ArticleId IdType="pmc">PMC5090220</ArticleId><ArticleId IdType="pubmed">27621269</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopal PP, Nirschl JJ, Klinman E, Holzbaur EL. Amyotrophic lateral sclerosis-linked mutations increase the viscosity of liquid-like TDP-43 RNP granules in neurons. Proc Natl Acad Sci USA. 2017;114(12):E2466&#x2013;E2475. doi: 10.1073/pnas.1614462114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1614462114</ArticleId><ArticleId IdType="pmc">PMC5373408</ArticleId><ArticleId IdType="pubmed">28265061</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. Hum Mol Genet. 2013;22(15):3112&#x2013;3122. doi: 10.1093/hmg/ddt166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt166</ArticleId><ArticleId IdType="pmc">PMC3699067</ArticleId><ArticleId IdType="pubmed">23575225</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H, Shibagaki Y, Hattori S, Matsuoka M. Nuclear TDP-43 causes neuronal toxicity by escaping from the inhibitory regulation by hnRNPs. Hum Mol Genet. 2015;24(6):1513&#x2013;1527. doi: 10.1093/hmg/ddu563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu563</ArticleId><ArticleId IdType="pubmed">25378556</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M. Reproducibility crisis: Blame it on the antibodies. Nature. 2015;521(7552):274&#x2013;276. doi: 10.1038/521274a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/521274a</ArticleId><ArticleId IdType="pubmed">25993940</ArticleId></ArticleIdList></Reference><Reference><Citation>Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature. 2012;483(7391):531&#x2013;533. doi: 10.1038/483531a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/483531a</ArticleId><ArticleId IdType="pubmed">22460880</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran FA, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013;154(6):1380&#x2013;1389. doi: 10.1016/j.cell.2013.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.08.021</ArticleId><ArticleId IdType="pmc">PMC3856256</ArticleId><ArticleId IdType="pubmed">23992846</ArticleId></ArticleIdList></Reference><Reference><Citation>Eom T, et al. NOVA-dependent regulation of cryptic NMD exons controls synaptic protein levels after seizure. Elife. 2013;2:e00178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552424</ArticleId><ArticleId IdType="pubmed">23359859</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolisnyk B, et al. Cholinergic regulation of hnRNPA2/B1 translation by M1 muscarinic receptors. J Neurosci. 2016;36(23):6287&#x2013;6296. doi: 10.1523/JNEUROSCI.4614-15.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4614-15.2016</ArticleId><ArticleId IdType="pmc">PMC6604881</ArticleId><ArticleId IdType="pubmed">27277805</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores BN, Li X, Malik AM, Martinez J, Beg AA, Barmada SJ. An intramolecular salt bridge linking TDP43 RNA binding, protein stability, and TDP43-dependent neurodegeneration. Cell Rep. 2019;27(4):1133&#x2013;1150.e8. doi: 10.1016/j.celrep.2019.03.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.03.093</ArticleId><ArticleId IdType="pmc">PMC6499398</ArticleId><ArticleId IdType="pubmed">31018129</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HY, Wang IF, Bose J, Shen CK. Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics. 2004;83(1):130&#x2013;139. doi: 10.1016/S0888-7543(03)00214-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0888-7543(03)00214-3</ArticleId><ArticleId IdType="pubmed">14667816</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Alton S, Altshuler M, Lewis J. Studies of alternative isoforms provide insight into TDP-43 autoregulation and pathogenesis. RNA. 2015;21(8):1419&#x2013;1432. doi: 10.1261/rna.047647.114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.047647.114</ArticleId><ArticleId IdType="pmc">PMC4509932</ArticleId><ArticleId IdType="pubmed">26089325</ArticleId></ArticleIdList></Reference><Reference><Citation>Avenda&#xf1;o-V&#xe1;zquez SE, Dhir A, Bembich S, Buratti E, Proudfoot N, Baralle FE. Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. Genes Dev. 2012;26(15):1679&#x2013;1684. doi: 10.1101/gad.194829.112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.194829.112</ArticleId><ArticleId IdType="pmc">PMC3418585</ArticleId><ArticleId IdType="pubmed">22855830</ArticleId></ArticleIdList></Reference><Reference><Citation>Bembich S, et al. Predominance of spliceosomal complex formation over polyadenylation site selection in TDP-43 autoregulation. Nucleic Acids Res. 2014;42(5):3362&#x2013;3371. doi: 10.1093/nar/gkt1343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1343</ArticleId><ArticleId IdType="pmc">PMC3950720</ArticleId><ArticleId IdType="pubmed">24369426</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfried NT, et al. Multiplex SILAC analysis of a cellular TDP-43 proteinopathy model reveals protein inclusions associated with SUMOylation and diverse polyubiquitin chains. Mol Cell Proteomics. 2010;9(4):705&#x2013;718. doi: 10.1074/mcp.M800390-MCP200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M800390-MCP200</ArticleId><ArticleId IdType="pmc">PMC2860236</ArticleId><ArticleId IdType="pubmed">20047951</ArticleId></ArticleIdList></Reference><Reference><Citation>Dammer EB, et al. Coaggregation of RNA-binding proteins in a model of TDP-43 proteinopathy with selective RGG motif methylation and a role for RRM1 ubiquitination. PLoS One. 2012;7(6):e38658. doi: 10.1371/journal.pone.0038658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0038658</ArticleId><ArticleId IdType="pmc">PMC3380899</ArticleId><ArticleId IdType="pubmed">22761693</ArticleId></ArticleIdList></Reference><Reference><Citation>la Cour T, Kiemer L, M&#xf8;lgaard A, Gupta R, Skriver K, Brunak S. Analysis and prediction of leucine-rich nuclear export signals. Protein Eng Des Sel. 2004;17(6):527&#x2013;536. doi: 10.1093/protein/gzh062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/protein/gzh062</ArticleId><ArticleId IdType="pubmed">15314210</ArticleId></ArticleIdList></Reference><Reference><Citation>Niopek D, Wehler P, Roensch J, Eils R, Di Ventura B. Optogenetic control of nuclear protein export. Nat Commun. 2016;7:10624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4748110</ArticleId><ArticleId IdType="pubmed">26853913</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, et al. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci. 2008;121(Pt 22):3778&#x2013;3785.</Citation><ArticleIdList><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, et al. Amelioration of toxicity in neuronal models of amyotrophic lateral sclerosis by hUPF1. Proc Natl Acad Sci USA. 2015;112(25):7821&#x2013;7826. doi: 10.1073/pnas.1509744112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1509744112</ArticleId><ArticleId IdType="pmc">PMC4485101</ArticleId><ArticleId IdType="pubmed">26056265</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik AM, Miguez RA, Li X, Ho YS, Feldman EL, Barmada SJ. Matrin 3-dependent neurotoxicity is modified by nucleic acid binding and nucleocytoplasmic localization. Elife. 2018;7:e35977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6050042</ArticleId><ArticleId IdType="pubmed">30015619</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp K, Safren N, Miguez R, Barmada S. Monitoring neuronal survival via longitudinal fluorescence microscopy. J Vis Exp. 2019;(143):59036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6594158</ArticleId><ArticleId IdType="pubmed">30735193</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen E. Multivariate survival analysis using Cox&#x2019;s regression model. Hepatology. 1987;7(6):1346&#x2013;1358. doi: 10.1002/hep.1840070628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.1840070628</ArticleId><ArticleId IdType="pubmed">3679094</ArticleId></ArticleIdList></Reference><Reference><Citation>Afroz T, et al. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nat Commun. 2017;8(1):45. doi: 10.1038/s41467-017-00062-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00062-0</ArticleId><ArticleId IdType="pmc">PMC5491494</ArticleId><ArticleId IdType="pubmed">28663553</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo PH, Doudeva LG, Wang YT, Shen CK, Yuan HS. Structural insights into TDP-43 in nucleic-acid binding and domain interactions. Nucleic Acids Res. 2009;37(6):1799&#x2013;1808. doi: 10.1093/nar/gkp013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkp013</ArticleId><ArticleId IdType="pmc">PMC2665213</ArticleId><ArticleId IdType="pubmed">19174564</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem. 2009;284(30):20329&#x2013;20339. doi: 10.1074/jbc.M109.010264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.010264</ArticleId><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci USA. 2009;106(18):7607&#x2013;7612. doi: 10.1073/pnas.0900688106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0900688106</ArticleId><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzo F, et al. Structural insights into the multi-determinant aggregation of TDP-43 in motor neuron-like cells. Neurobiol Dis. 2016;94:63&#x2013;72. doi: 10.1016/j.nbd.2016.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.06.006</ArticleId><ArticleId IdType="pubmed">27317832</ArticleId></ArticleIdList></Reference><Reference><Citation>Budini M, Romano V, Quadri Z, Buratti E, Baralle FE. TDP-43 loss of cellular function through aggregation requires additional structural determinants beyond its C-terminal Q/N prion-like domain. Hum Mol Genet. 2015;24(1):9&#x2013;20. doi: 10.1093/hmg/ddu415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu415</ArticleId><ArticleId IdType="pmc">PMC4262490</ArticleId><ArticleId IdType="pubmed">25122661</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CK, et al. The N-terminus of TDP-43 promotes its oligomerization and enhances DNA binding affinity. Biochem Biophys Res Commun. 2012;425(2):219&#x2013;224. doi: 10.1016/j.bbrc.2012.07.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2012.07.071</ArticleId><ArticleId IdType="pubmed">22835933</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431(7010):805&#x2013;810. doi: 10.1038/nature02998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02998</ArticleId><ArticleId IdType="pubmed">15483602</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, Pagani F, Baralle FE. TDP43 depletion rescues aberrant CFTR exon 9 skipping. FEBS Lett. 2006;580(5):1339&#x2013;1344. doi: 10.1016/j.febslet.2006.01.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2006.01.052</ArticleId><ArticleId IdType="pubmed">16458894</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, D&#xf6;rk T, Zuccato E, Pagani F, Romano M, Baralle FE. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001;20(7):1774&#x2013;1784. doi: 10.1093/emboj/20.7.1774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/20.7.1774</ArticleId><ArticleId IdType="pmc">PMC145463</ArticleId><ArticleId IdType="pubmed">11285240</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14(4):459&#x2013;468. doi: 10.1038/nn.2779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 2011;30(2):277&#x2013;288. doi: 10.1038/emboj.2010.310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2010.310</ArticleId><ArticleId IdType="pmc">PMC3025456</ArticleId><ArticleId IdType="pubmed">21131904</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21(4):552&#x2013;563. doi: 10.1038/s41593-018-0113-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0113-5</ArticleId><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Krach F, et al. Transcriptome-pathology correlation identifies interplay between TDP-43 and the expression of its kinase CK1E in sporadic ALS. Acta Neuropathol. 2018;136(3):405&#x2013;423. doi: 10.1007/s00401-018-1870-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1870-7</ArticleId><ArticleId IdType="pmc">PMC6215775</ArticleId><ArticleId IdType="pubmed">29881994</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Erchia AM, et al. Massive transcriptome sequencing of human spinal cord tissues provides new insights into motor neuron degeneration in ALS. Sci Rep. 2017;7(1):10046. doi: 10.1038/s41598-017-10488-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-10488-7</ArticleId><ArticleId IdType="pmc">PMC5577269</ArticleId><ArticleId IdType="pubmed">28855684</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, et al. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat Neurosci. 2015;18(8):1175&#x2013;1182. doi: 10.1038/nn.4065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4065</ArticleId><ArticleId IdType="pmc">PMC4830686</ArticleId><ArticleId IdType="pubmed">26192745</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, et al. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2014;111(12):E1121&#x2013;E1129. doi: 10.1073/pnas.1322641111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1322641111</ArticleId><ArticleId IdType="pmc">PMC3970502</ArticleId><ArticleId IdType="pubmed">24616503</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HR, Chiang WC, Chou PC, Wang WJ, Huang JR. TAR DNA-binding protein 43 (TDP-43) liquid-liquid phase separation is mediated by just a few aromatic residues. J Biol Chem. 2018;293(16):6090&#x2013;6098. doi: 10.1074/jbc.AC117.001037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.AC117.001037</ArticleId><ArticleId IdType="pmc">PMC5912450</ArticleId><ArticleId IdType="pubmed">29511089</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L, et al. Poly(ADP-ribose) prevents pathological phase separation of TDP-43 by promoting liquid demixing and stress granule localization. Mol Cell. 2018;71(5):703&#x2013;717.e9. doi: 10.1016/j.molcel.2018.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2018.07.002</ArticleId><ArticleId IdType="pmc">PMC6128762</ArticleId><ArticleId IdType="pubmed">30100264</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella AE, Zerze GH, Mittal J, Fawzi NL. ALS mutations disrupt phase separation mediated by &#x3b1;-helical structure in the TDP-43 low-complexity C-terminal domain. Structure. 2016;24(9):1537&#x2013;1549. doi: 10.1016/j.str.2016.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2016.07.007</ArticleId><ArticleId IdType="pmc">PMC5014597</ArticleId><ArticleId IdType="pubmed">27545621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, et al. RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron. 2019;102(2):321&#x2013;338.e8. doi: 10.1016/j.neuron.2019.01.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.01.048</ArticleId><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, McCaffery JM, Lindquist S, Gitler AD. A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci USA. 2008;105(17):6439&#x2013;6444. doi: 10.1073/pnas.0802082105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0802082105</ArticleId><ArticleId IdType="pmc">PMC2359814</ArticleId><ArticleId IdType="pubmed">18434538</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal S, Kuo PH, Chu LY, Golzarroshan B, Jain M, Yuan HS. RNA recognition motifs of disease-linked RNA-binding proteins contribute to amyloid formation. Sci Rep. 2019;9(1):6171. doi: 10.1038/s41598-019-42367-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-42367-8</ArticleId><ArticleId IdType="pmc">PMC6467989</ArticleId><ArticleId IdType="pubmed">30992467</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmann TM, Alberti S. Prion-like low-complexity sequences: Key regulators of protein solubility and phase behavior. J Biol Chem. 2019;294(18):7128&#x2013;7136. doi: 10.1074/jbc.TM118.001190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.TM118.001190</ArticleId><ArticleId IdType="pmc">PMC6509491</ArticleId><ArticleId IdType="pubmed">29921587</ArticleId></ArticleIdList></Reference><Reference><Citation>Riback JA, et al. Stress-triggered phase separation is an adaptive, evolutionarily tuned response. Cell. 2017;168(6):1028&#x2013;1040.e19. doi: 10.1016/j.cell.2017.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.02.027</ArticleId><ArticleId IdType="pmc">PMC5401687</ArticleId><ArticleId IdType="pubmed">28283059</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroschwald S, et al. Different material states of Pub1 condensates define distinct modes of stress adaptation and recovery. Cell Rep. 2018;23(11):3327&#x2013;3339. doi: 10.1016/j.celrep.2018.05.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.05.041</ArticleId><ArticleId IdType="pubmed">29898402</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmann TM, et al. Phase separation of a yeast prion protein promotes cellular fitness. Science. 2018;359(6371):eaao5654. doi: 10.1126/science.aao5654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aao5654</ArticleId><ArticleId IdType="pubmed">29301985</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, Lee VM. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem. 2008;283(19):13302&#x2013;13309. doi: 10.1074/jbc.M800342200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M800342200</ArticleId><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornerod M, Ohno M, Yoshida M, Mattaj IW. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell. 1997;90(6):1051&#x2013;1060. doi: 10.1016/S0092-8674(00)80371-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)80371-2</ArticleId><ArticleId IdType="pubmed">9323133</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinarbasi ES, Ca&#x11f;atay T, Fung HYJ, Li YC, Chook YM, Thomas PJ. Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization. Sci Rep. 2018;8(1):7083. doi: 10.1038/s41598-018-25008-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-25008-4</ArticleId><ArticleId IdType="pmc">PMC5935693</ArticleId><ArticleId IdType="pubmed">29728608</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#x131;rl&#x131; K, et al. A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning. Elife. 2015;4:e11466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4764573</ArticleId><ArticleId IdType="pubmed">26673895</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakar K, Karaca S, Port SA, Urlaub H, Kehlenbach RH. Identification of CRM1-dependent nuclear export cargos using quantitative mass spectrometry. Mol Cell Proteomics. 2013;12(3):664&#x2013;678. doi: 10.1074/mcp.M112.024877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M112.024877</ArticleId><ArticleId IdType="pmc">PMC3591659</ArticleId><ArticleId IdType="pubmed">23242554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, et al. Human, Drosophila, and C.elegans TDP43: nucleic acid binding properties and splicing regulatory function. J Mol Biol. 2005;348(3):575&#x2013;588. doi: 10.1016/j.jmb.2005.02.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2005.02.038</ArticleId><ArticleId IdType="pubmed">15826655</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A, et al. A single N-terminal phosphomimic disrupts TDP-43 polymerization, phase separation, and RNA splicing. EMBO J. 2018;37(5):e97452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5830921</ArticleId><ArticleId IdType="pubmed">29438978</ArticleId></ArticleIdList></Reference><Reference><Citation>Leigh PN, et al. Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain. 1991;114(Pt 2):775&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">1646064</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits J, Paul P, Jorg C. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology. 2007;68(19):1571&#x2013;1575. doi: 10.1212/01.wnl.0000260965.20021.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000260965.20021.47</ArticleId><ArticleId IdType="pubmed">17485643</ArticleId></ArticleIdList></Reference><Reference><Citation>Udan M, Baloh RH. Implications of the prion-related Q/N domains in TDP-43 and FUS. Prion. 2011;5(1):1&#x2013;5. doi: 10.4161/pri.5.1.14265.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/pri.5.1.14265</ArticleId><ArticleId IdType="pmc">PMC3037998</ArticleId><ArticleId IdType="pubmed">21135580</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, Kaneko K, Watanabe S, Yamanaka K, Nukina N. A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J Biol Chem. 2011;286(21):18664&#x2013;18672. doi: 10.1074/jbc.M111.231209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.231209</ArticleId><ArticleId IdType="pmc">PMC3099683</ArticleId><ArticleId IdType="pubmed">21454603</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Kametani F, Arai T, Akiyama H, Hasegawa M. Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet. 2009;18(18):3353&#x2013;3364. doi: 10.1093/hmg/ddp275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp275</ArticleId><ArticleId IdType="pubmed">19515851</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji H, et al. Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain. 2012;135(Pt 11):3380&#x2013;3391.</Citation><ArticleIdList><ArticleId IdType="pubmed">23035040</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, et al. Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 proteinopathies. J Biol Chem. 2009;284(13):8516&#x2013;8524. doi: 10.1074/jbc.M809462200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M809462200</ArticleId><ArticleId IdType="pmc">PMC2659210</ArticleId><ArticleId IdType="pubmed">19164285</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang IF, Chang HY, Hou SC, Liou GG, Way TD, James Shen CK. The self-interaction of native TDP-43 C terminus inhibits its degradation and contributes to early proteinopathies. Nat Commun. 2012;3:766.</Citation><ArticleIdList><ArticleId IdType="pubmed">22473010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YT, et al. The truncated C-terminal RNA recognition motif of TDP-43 protein plays a key role in forming proteinaceous aggregates. J Biol Chem. 2013;288(13):9049&#x2013;9057. doi: 10.1074/jbc.M112.438564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.438564</ArticleId><ArticleId IdType="pmc">PMC3610977</ArticleId><ArticleId IdType="pubmed">23372158</ArticleId></ArticleIdList></Reference><Reference><Citation>Berning BA, Walker AK. The pathobiology of TDP-43 C-terminal fragments in ALS and FTLD. Front Neurosci. 2019;13:335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6470282</ArticleId><ArticleId IdType="pubmed">31031584</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, et al. A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nat Commun. 2012;3:1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">23250437</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, et al. Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol. 2008;173(1):182&#x2013;194. doi: 10.2353/ajpath.2008.080003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.080003</ArticleId><ArticleId IdType="pmc">PMC2438296</ArticleId><ArticleId IdType="pubmed">18535185</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacco E, Martin SR, Thorogate R, Pastore A. The RNA-recognition motifs of TAR DNA-binding protein 43 may play a role in the aberrant self-assembly of the protein. Front Mol Neurosci. 2018;11:372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6190850</ArticleId><ArticleId IdType="pubmed">30356856</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaguri H, et al. The extreme N-terminus of TDP-43 mediates the cytoplasmic aggregation of TDP-43 and associated toxicity in vivo. Brain Res. 2016;1647:57&#x2013;64. doi: 10.1016/j.brainres.2016.04.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.04.069</ArticleId><ArticleId IdType="pmc">PMC5003772</ArticleId><ArticleId IdType="pubmed">27155453</ArticleId></ArticleIdList></Reference><Reference><Citation>Shodai A, et al. Aberrant assembly of RNA recognition motif 1 links to pathogenic conversion of TAR DNA-binding protein of 43 kDa (TDP-43) J Biol Chem. 2013;288(21):14886&#x2013;14905. doi: 10.1074/jbc.M113.451849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.451849</ArticleId><ArticleId IdType="pmc">PMC3663511</ArticleId><ArticleId IdType="pubmed">23558684</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol. 2007;66(3):177&#x2013;183. doi: 10.1097/01.jnen.0000248554.45456.58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jnen.0000248554.45456.58</ArticleId><ArticleId IdType="pubmed">17356379</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishihira Y, et al. Sporadic amyotrophic lateral sclerosis: two pathological patterns shown by analysis of distribution of TDP-43-immunoreactive neuronal and glial cytoplasmic inclusions. Acta Neuropathol. 2008;116(2):169&#x2013;182. doi: 10.1007/s00401-008-0385-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0385-z</ArticleId><ArticleId IdType="pubmed">18481073</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, et al. TDP-43-immunoreactive neuronal and glial inclusions in the neostriatum in amyotrophic lateral sclerosis with and without dementia. Acta Neuropathol. 2008;115(1):115&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">17786458</ArticleId></ArticleIdList></Reference><Reference><Citation>Serio A, et al. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc Natl Acad Sci USA. 2013;110(12):4697&#x2013;4702. doi: 10.1073/pnas.1300398110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1300398110</ArticleId><ArticleId IdType="pmc">PMC3607024</ArticleId><ArticleId IdType="pubmed">23401527</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997;18(2):327&#x2013;338. doi: 10.1016/S0896-6273(00)80272-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80272-X</ArticleId><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H, et al. Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet. 2003;12(19):2519&#x2013;2532. doi: 10.1093/hmg/ddg267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddg267</ArticleId><ArticleId IdType="pubmed">12915461</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland DS, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS) Proc Natl Acad Sci USA. 2002;99(3):1604&#x2013;1609. doi: 10.1073/pnas.032539299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.032539299</ArticleId><ArticleId IdType="pmc">PMC122237</ArticleId><ArticleId IdType="pubmed">11818550</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardo AC, et al. Loss of the astrocyte glutamate transporter GLT1 modifies disease in SOD1(G93A) mice. Exp Neurol. 2006;201(1):120&#x2013;130. doi: 10.1016/j.expneurol.2006.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2006.03.028</ArticleId><ArticleId IdType="pubmed">16753145</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med. 1992;326(22):1464&#x2013;1468. doi: 10.1056/NEJM199205283262204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199205283262204</ArticleId><ArticleId IdType="pubmed">1349424</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol. 1995;38(1):73&#x2013;84. doi: 10.1002/ana.410380114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410380114</ArticleId><ArticleId IdType="pubmed">7611729</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>